To the Editor.
—I read with interest the article by Trouillas et al1 in the November 1988 issue of the Archives. Their findings, akin to the ones they had previously published,2 are interesting and potentially of great significance for patients with Friedreich's ataxia, olivopontocerebellar degeneration, and other degenerative diseases affecting the cerebellum.Trouillas and coworkers' findings are at variance with a study that we performed.3 Inspired by Trouillas and coworkers' previously reported findings, we sought to corroborate them. Eight patients, four with Friedreich's ataxia, one with sporadic adult-onset cerebellar degeneration of the parenchymal (Holmes) type, and one each with posttraumatic, postinfectious, and multiple sclerosis—related cerebellar deficits, were administered the levorotatory form of 5-hydroxytryptophan, together with the peripheral decarboxylase inhibitor, benserazide, in dosages identical to those used by Trouillas et al.2 In one case, half that dose was used as the higher dose-induced psychosis.Our findings
Klein P. Cerebellar Ataxia. Arch Neurol. 1989;46(11):1166. doi:https://doi.org/10.1001/archneur.1989.00520470016011
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: